If you’ve ever come home from a trip to Europe or Asia clutching a sunscreen that felt nothing like anything available at home—lighter, sheerer, more luxurious—you’ve already felt the gap that this story is about.
For more than two decades, the U.S. sunscreen market has operated with a limited set of UV filters. While formulators in Europe and Asia gained access to newer, more sophisticated ingredients, American chemists and brands were left working with the same tools as the 1990s. The result: heavier textures, more white cast and a UVA protection gap that dermatologists have worried about for years.
That may be about to change. The FDA has proposed approving bemotrizinol—a chemical, broad-spectrum UV filter already used safely in dozens of countries—with a final decision expected this summer. To understand what’s at stake, we spoke with a cosmetic chemist, the team at America’s number-one sunscreen brand and a dermatologist who has been watching this approval closely.
Why It’s Taking So Long
First, the U.S. is unusual in how it treats sunscreen. While much of the world classifies these products as cosmetics, the FDA regulates them as over-the-counter drugs, which means every active ingredient must meet a drug-level standard for safety and efficacy before it can appear on a label.
That distinction matters enormously. It’s why, despite bemotrizinol being used in sunscreens internationally for roughly two decades, its U.S. debut is taking so long to arrive.
“The FDA’s review of bemotrizinol is important because it suggests regulators are trying to modernize sunscreen options without lowering the safety bar,” says Dallas dermatologist Elizabeth Houshmand, MD. “Bemotrizinol’s review shows that innovation is possible when newer filters are supported by modern safety, absorption, toxicology and efficacy data.”
Cosmetic chemist Kelly Dobos, who has closely followed the ingredient’s review, agrees. “The nearly 20-year path bemotrizinol has taken reflects just how rigorous the U.S. sunscreen approval process has become. The FDA did not shortcut safety in order to approve a modern filter—bemotrizinol is arguably now one of the most comprehensively evaluated sunscreen active ingredients the U.S. has ever reviewed.”
That rigor, however, comes with a cost. Six other UV filter candidates were pursued under a process called the Time and Extent Application (TEA) in the early 2000s, and all of those efforts have since been largely abandoned. The process proved too slow and too expensive for ingredient manufacturers to see through to completion.
Erica Sinclair, VP of Regulatory Affairs at Kenvue North America, the parent company of Neutrogena, sees the proposed approval as a meaningful signal from within the agency itself. “One of the initiatives taken by the Office of Nonprescription Drugs at FDA is to advance sunscreen innovation,” she explains. “The pending approval of this active ingredient shows FDA recognizes the public health benefits of sunscreen use in lowering the incidence of some preventable cancers in the United States.”
The Science That Changed the Conversation
One reason past sunscreen ingredients have drawn scrutiny is systemic absorption—the question of how much of what you apply to your skin ends up in your bloodstream. Studies over the past several years showed that some widely used chemical filters can be detected at measurable levels in the body, prompting consumer concerns and regulatory attention even for ingredients with long safety records.
Bemotrizinol was designed, from the start, with this problem in mind. “Past concerns around sunscreen ingredients have focused on systemic absorption, especially after studies showed that some filters can be detected in the bloodstream,” says Dr. Houshmand. “Bemotrizinol appears to address that concern because it has low skin penetration and a favorable irritation profile. Its evaluation reflects newer FDA expectations, including maximal-use testing and updated safety data, rather than relying only on international use history.”
Dobos calls out the engineering behind that performance. “Bemotrizinol was specifically formulated to have a higher molecular weight to minimize skin penetration. That design intent proved successful—even in studies investigating extreme use conditions, known as maximal usage trials, it showed very low systemic exposure.”
Those maximal usage trials, or MUsTs, are now a central part of how the FDA evaluates sunscreen actives, essentially stress-testing what happens to the body when someone applies the highest reasonable amount, as frequently as they realistically might. Bemotrizinol’s performance under those conditions, supported by decades of international post-market data and modern toxicological assessments, gave regulators the confidence to move forward.
What It Means for Your Sunscreen Shelf
For most people, the most immediate impact of bemotrizinol’s approval will be felt not in a lab report, but in a texture. The filters currently available in U.S. sunscreens come with well-known trade-offs: avobenzone can degrade in sunlight without stabilizers; zinc oxide and titanium dioxide provide excellent protection, but often leave a white cast that limits adherence, particularly among people with deeper skin tones.
Bemotrizinol absorbs efficiently across both UVA and UVB wavelengths and can help stabilize other filters in a formula, giving formulators far more flexibility to build high-SPF, truly broad-spectrum products without relying as heavily on ingredients consumers find cosmetically challenging.
“If approved, bemotrizinol could meaningfully improve U.S. sunscreen formulation,” says Dr. Houshmand. “It is broad spectrum, photostable and can help strengthen UVA protection while supporting high-SPF, more cosmetically elegant formulas. That matters because the best sunscreen is ultimately the one patients will use consistently.”
Dobos echoes that point. “Lighter textures and less whitening are attributes that matter enormously for consumers. Cosmetic elegance is often the strongest predictor of whether people will actually use a sunscreen as directed, and that’s what ultimately protects skin.”
A note on UVA: While U.S. sunscreens are labeled for SPF, which measures UVB protection, UVA protection is less standardized. UVA rays penetrate deeper into the skin and are a primary driver of photoaging and a contributor to skin cancer risk. Bemotrizinol’s strong UVA absorption could meaningfully raise the ceiling for broad-spectrum protection in American formulas.
Neutrogena is already preparing for that shift. “Bemotrizinol has high solubility in cosmetic emollients, which supports superior water resistance and long-lasting broad-spectrum sun protection,” says Sinclair. “Once bemotrizinol is approved, Neutrogena will integrate this filter into its sunscreen innovation pipeline, leveraging its aesthetic benefits and gentle formulation profile.”
Closing the Global Gap—and What Comes Next
For global brands, the U.S. sunscreen market has long required a workaround: formulate one product for markets where modern filters are available, and a different, more limited version for American shelves. That split has been costly, and it has left U.S. consumers with products that don’t always match what those same brands offer internationally.
“Europe and Asia have had access to more advanced filters for years, which has allowed lighter textures, better UVA coverage, and fewer issues like chalkiness or heavy feel,” says Dr. Houshmand. “Adding bemotrizinol would make U.S. sunscreens more globally competitive.”
Dobos agrees, while noting how much further there is to go. “Approval of bemotrizinol allows U.S. products to move closer to global performance expectations, especially in UVA protection. U.S. formulations will be able to achieve aesthetics that more closely resemble their international counterparts, but we still could use a few more modern filters to truly get on par with the rest of the world.”
On whether this is a one-time event or the beginning of something larger, Dr. Houshmand is carefully optimistic. “I see this as potentially an opportunity…possibly the first sign that the U.S. sunscreen monograph process is becoming more responsive to modern science. If finalized, bemotrizinol could open the door for additional next-generation UV filters to be reviewed.”
Dobos cautions that the path forward remains steep. “We really have to thank dsm-firmenich [a key player behind bemotrizinol’s development] for bringing bemotrizinol to the finish line. The story shows that approval may be possible, but it also emphasizes the complications that the lengthy and costly process brings.” No other candidate is currently being supported through the process with the same level of investment.
Kenvue’s Sinclair points to a broader coalition forming around the issue. At the 2026 American Academy of Dermatology Annual Meeting, dermatologists and researchers presented on the clinical value of daily sunscreen use, signaling growing institutional momentum. “We believe the industry as a whole is committed to bringing even more UV filters into the U.S.,” she says.
The final FDA decision is expected this summer. If it comes through as anticipated, American sunscreen will never quite be the same—and for the first time in a generation, the best formulas on U.S. shelves may actually rival the ones you’ve been sneaking home from abroad.
